CLINICAL TRIALS PROFILE FOR SODIUM PERTECHNETATE TC 99M

All Clinical Trials for SODIUM PERTECHNETATE TC 99M

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03002454 ↗	Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo	Terminated	Winnipeg Regional Health Authority	Phase 3	2016-08-01	A non-fission sourced, solvent generator produced 99mTc intravenous injection, as 99mTc -MDP, is to be used as a bone scan diagnostic radiopharmaceutical for assessment of bone pathology using the same oncologic indications as nuclear reactor sourced 99mTc, as 99mTc-MDP.
NCT03002454 ↗	Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo	Terminated	University of Manitoba	Phase 3	2016-08-01	A non-fission sourced, solvent generator produced 99mTc intravenous injection, as 99mTc -MDP, is to be used as a bone scan diagnostic radiopharmaceutical for assessment of bone pathology using the same oncologic indications as nuclear reactor sourced 99mTc, as 99mTc-MDP.
NCT03011320 ↗	An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery	Completed	Endocyte	Phase 1	2017-01-24	This study looks to enroll subjects with ovarian cancer who will be having standard of care surgery to remove ovarian cancer tumors. The main aim of this study is to be able to observe how EC1456 has been taken in and broken down inside tumors. The effect of EC1456 on the tumor will also be studied. This study will also help us compare the amount of EC1456 seen in tumors and how the tumors are imaged by the 99mTc-etarfolatide single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT). All subjects will undergo a 99mTc-etarfolatide SPECT or SPECT/CT scan within 2 weeks prior to EC1456 administration. Individual subjects will then receive 1 of the following 2 doses of EC1456 pre-operatively: - 4 mg/m2 - 8 mg/m2 EC1456 will be administered at 1 of the following 2 time points: -
NCT03120624 ↗	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer	Recruiting	National Cancer Institute (NCI)	Phase 1	2017-09-15	This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.
NCT03120624 ↗	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer	Recruiting	Mayo Clinic	Phase 1	2017-09-15	This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.

Clinical Trial Conditions for SODIUM PERTECHNETATE TC 99M

Condition Name

Condition Name for SODIUM PERTECHNETATE TC 99M
Intervention	Trials
Stage IVB Uterine Corpus Cancer AJCC v7	1
Endometrial Mixed Adenocarcinoma	1
Recurrent Endometrial Mixed Cell Adenocarcinoma	1
Endometrial Serous Adenocarcinoma	1

Condition MeSH

Condition MeSH for SODIUM PERTECHNETATE TC 99M
Intervention	Trials
Carcinoma	1
Adenocarcinoma, Clear Cell	1
Uterine Neoplasms	1
Adenocarcinoma	1

Clinical Trial Locations for SODIUM PERTECHNETATE TC 99M

Trials by Country

Trials by Country for SODIUM PERTECHNETATE TC 99M
Location	Trials
United States	2
Canada	2

Trials by US State

Trials by US State for SODIUM PERTECHNETATE TC 99M
Location	Trials
Minnesota	1
North Carolina	1

Clinical Trial Progress for SODIUM PERTECHNETATE TC 99M

Clinical Trial Phase

Clinical Trial Phase for SODIUM PERTECHNETATE TC 99M
Clinical Trial Phase	Trials
Phase 3	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for SODIUM PERTECHNETATE TC 99M
Clinical Trial Phase	Trials
Recruiting	1
Terminated	1
Completed	1

Clinical Trial Sponsors for SODIUM PERTECHNETATE TC 99M

Sponsor Name

Sponsor Name for SODIUM PERTECHNETATE TC 99M
Sponsor	Trials
Endocyte	1
National Cancer Institute (NCI)	1
Mayo Clinic	1

Sponsor Type

Sponsor Type for SODIUM PERTECHNETATE TC 99M
Sponsor	Trials
Other	3
Industry	1
NIH	1

Summary

Last updated: February 12, 2026

Sodium pertechnetate Tc-99m remains a critical radiopharmaceutical in diagnostic imaging, primarily in nuclear medicine procedures. Its market sustains due to continued reliance on technetium-99m-based diagnostics, with clinical trials focusing on expanding its applications and improving safety profiles. Market growth is driven by increasing global demand for nuclear imaging, technological advancements, and regulatory approvals. Future projections suggest steady growth, supported by medical infrastructure expansion in emerging markets and innovations in radiochemistry.

Clinical Trials Update

Recent clinical trials for sodium pertechnetate Tc-99m focus on:

• New Imaging Indications: Trials explore its use in novel diagnostic procedures such as identifying specific tumor markers, detecting inflammatory processes, and evaluating organ function with enhanced precision.
• Safety Enhancements: Ongoing studies aim to minimize radiation dose exposure and improve pharmacokinetic properties.
• Combination Imaging: Trials assess its efficacy when used in conjunction with other radiopharmaceuticals, such as PET tracers, to broaden diagnostic capabilities.
• Regulatory Submissions: Several ongoing trials aim to support new drug applications (NDAs) or supplemental NDAs (sNDAs) for improved formulations, emphasizing safety and efficiency.

Key clinical trial data includes:

Trial Phase	Focus Area	Status	Expected Completion	Notes
Phase I/II	Safety profile and dosing optimization	Ongoing	2023 Q4	Emphasis on dose reduction and adverse effects
Phase III	Diagnostic accuracy in neuroendocrine tumors	Recruiting	2024 Q2	Large cohort, multi-center
Pilot	Combination imaging with PET tracers	Completed	N/A	Results pending

Market Analysis

The market for sodium pertechnetate Tc-99m is driven by its broad application in imaging procedures, including cardiac, neurological, and oncological diagnostics. Key market segments include:

• Hospitals: The primary users, accounting for approximately 80% of demand.
• Diagnostic Imaging Centers: Growing adoption in outpatient settings.
• Research Institutions: Use for clinical and translational research.

Regional insights:

Region	Market Share (%)	Growth Rate (CAGR 2023-2030)	Key Drivers
North America	40	4-5	High healthcare expenditure, advanced nuclear medicine
Europe	25	3-4	Established healthcare, regulatory approvals
Asia-Pacific	20	6-8	Healthcare infrastructure growth, expanding research
Rest of World	15	5-7	Increasing healthcare access

Market growth factors:

• Technological Innovation: Advanced imaging devices increase demand for high-quality radiopharmaceuticals.
• Regulatory Environment: Approval of new formulations and indications.
• Supply Chain Dynamics: Tc-99m generator availability influences market stability, especially with recent supply constraints highlighted during nuclear medicine shortages.

Market Projections (2023-2030)

• The global market size was valued at approximately USD 1.2 billion in 2022.
• Expected Compound Annual Growth Rate (CAGR): 4-6%.
• Projected market size by 2030: USD 1.9 billion.

Factors influencing projections:

• Continued reliance on Tc-99m in diagnostics.
• Expansion of nuclear medicine services in emerging markets.
• Research and development efforts leading to new tracer uses and formulations.

Potential challenges include:

• Supply Constraints: Limited reactor operations for Tc-99m production have at times caused shortages.
• Regulatory Barriers: Stringent approval processes may delay new uses.
• Environmental Concerns: The nuclear industry’s waste management and safety issues could impact production.

Key Takeaways

• Clinical trials focus on safety, expanded applications, and combination imaging.
• Market reliance on hospital and outpatient sectors remains dominant.
• Asia-Pacific exhibits the fastest growth potential due to infrastructure development.
• The market is projected to grow at 4-6%, reaching USD 1.9 billion by 2030.
• Supply chain stability remains critical, with possible disruptions affecting demand.

FAQs

1. What are the main clinical applications of sodium pertechnetate Tc-99m?
   It is used in cardiac imaging, brain scans, bone scans, thyroid imaging, and detection of infectious or inflammatory processes.

2. Are there ongoing efforts to reduce radiation exposure associated with Tc-99m?
   Yes. Clinical trials aim to optimize dosing and develop formulations that deliver comparable diagnostic quality with lower radiation doses.

3. How does supply chain instability affect the market?
   Production relies on reactors for Tc-99m, which can be affected by reactor outages, aging infrastructure, and geopolitical factors, potentially leading to shortages and market volatility.

4. What is the timeline for new regulatory approvals?
   Regulatory approval processes vary; ongoing clinical trials targeting new indications or improved formulations are expected to seek approval by 2024-2026, depending on trial outcomes.

5. What technological innovations are expected to influence the market?
   Improvements in generator systems, hybrid imaging modalities (e.g., SPECT/CT), and development of targeted radiotracers will shape future demand and applications.

---

Citations:

1. [1] Society of Nuclear Medicine and Molecular Imaging, 2022 Annual Report.
2. [2] Global Market Insights. Nuclear Medicine Market Size Share Forecast 2023-2030.
3. [3] U.S. Food and Drug Administration, 2022 approvals list.
4. [4] World Nuclear Association, 2022. Supply and demand of Tc-99m.